Rilzabrutinib not checked

Sanofi · SAR444671 · PRN1008

FollowEvery change as it happens, and a Monday email
Stage
in the US
Next date
Phase 3 trial completes
Trials
11 active
23 in total · 10 in the EU
Targets
 

What this is

How it works
Blocks a kinase, an enzyme that passes "grow" or "activate" signals inside cells. Most are cancer drugs.Kinase Inhibitor FDA class
Tested for
Immune Thrombocytopenia (2 trials), Sickle Cell Disease, Autoimmune Haemolytic Anaemia, Immunoglobulin G4 Related Disease, Immunodeficiency Common Variable, Warm Autoimmune Hemolytic Anemia (wAIHA), Focal Segmental Glomerulosclerosis, Glomerulonephritis Minimal Lesion and 2 more
Main trialPhase 3
“This is an open-label, multi-center, single group, Phase 3 study for treatment with rilzabrutinib. The purpose of this study is to provide continuation of rilzabrutinib treatment to adult participants with ITP who have completed the LTE of the LUNA 3 study in Japan, demonstrating clinically meaningful benefit as judged by the Investigator.”In the company’s words, NCT07216079 on ClinicalTrials.gov
Other names
SAR444671 · PRN1008 · PRN1008/SAR444671 · BTK inhibitor

Other drugs for Immune Thrombocytopenia

All 32 drugs for Immune Thrombocytopenia

Coming up9

Changes1

Last 90 days

Trials23

TrialPhaseCompletesWhat it tests
Phase 3Active, not recruiting 25 Nov 2026 Rilzabrutinib for the Adult Participants With Chronic ITP Who Have Completed Phase 3 Study in Japan
Phase 3Recruiting 23 Jul 2027 The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease
Phase 3Recruiting 5 Nov 2027 Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment
Phase 3Recruiting 31 May 2028 A Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Oral Rilzabrutinib Compared With Placebo in Participants 18 Years of Age and Older With Warm Autoimmune Hemolytic Anemia
Phase 3Recruiting 28 Jun 2028 A 52-week Study of Rilzabrutinib Efficacy and Safety Compared to Placebo in Adults Diagnosed With IgG4-related Disease
Phase 2/3Not yet recruiting 10 May 2035 Phase 2 and 3 Placebo Controlled & Long-term Extension Study of Rilzabrutinib in Adults With iCVID to Evaluate Efficacy, Safety, and Tolerability
Phase 2Active, not recruiting 23 May 2024 Efficacy, Safety and Pharmacokinetics of Rilzabrutinib in Patients With Warm Autoimmune Hemolytic Anemia (wAIHA)
Phase 2Recruiting 23 Dec 2026 A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease
Phase 2Recruiting 11 Feb 2027 A Study to Investigate the Efficacy and Safety of Rilzabrutinib in Adult Participants With Graves' Disease
Phase 1Active, not recruiting 3 Nov 2026 An Open-label DDI Study to Investigate the Effect of Rilzabrutinib on P-gp, BCRP, OATP1B1 and OATP1B3 Inhibition
Phase 1Recruiting 21 Apr 2027 Study to Assess the Plasma Concentration of Rilzabrutinib Given as a Tablet to Adult Participants With Severe Renal Impairment Compared to Matched Participants With Normal Renal Function
Phase 3Terminated 30 Jul 2021 A Study of PRN1008 in Patients With Pemphigus
Phase 3Completed 15 Jan 2025 Study to Evaluate Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP)
Phase 2Completed 18 Dec 2019 A Study of PRN1008 in Adult Patients With Pemphigus Vulgaris
Phase 2Completed 31 Jan 2023 A Study of Rilzabrutinib in Adult Patients With Immune Thrombocytopenia (ITP)
Phase 2Completed 23 Jun 2023 Proof of Concept Study of Rilzabrutinib in Adult Patients With Moderate-to-severe Atopic Dermatitis
Phase 2Completed 19 Jul 2023 Rilzabrutinib for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine
Phase 2Completed 6 Feb 2024 Proof of Concept Study of Rilzabrutinib in Adult Participants With Moderate-to-severe Asthma
Phase 2Completed 15 Oct 2024 Open Label Two-Arm Study to Evaluate Rilzabrutinib in IgG4-Related Disease Participants
Phase 1Completed 23 Mar 2021 A Study to Evaluate the Effect of Mild and Moderate Hepatic Impairment on the Single-Dose Pharmacokinetics of Rilzabrutinib (PRN1008)
Phase 1Completed 12 Apr 2021 Pharmacokinetics (PK) of Rilzabrutinib (PRN1008) in Healthy Japanese and Caucasian Subjects
Phase 1Completed 21 May 2021 Food Effect and Relative Bioavailability Study of Rilzabrutinib in Healthy Participants
Phase 1Completed 23 Apr 2024 A Food Effect and Relative Bioavailability Study of Rilzabrutinib in Healthy Participants
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Rilzabrutinib

Following is part of Solo: you see every change to Rilzabrutinib the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in